Please assess the completion status of the following clinical trial:

Trial Title: Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Systemic Sclerosis diagnosed by the American College of Rheumatology consensus statement including any of the following:~   * Limited~  * Diffuse~  * Sine Scleroderma~2. Patients must be willing and able to undergo right heart catheterization with lower extremity cycle ergometry~3. Mean pulmonary artery pressure (mPAP) \> 30mmHg with exercise; PCWP ≤ 15mmHg on RHC at rest~4. Men and women, ages 18 years of age or older~5. Standard adjunctive medications will be allowed concurrently in this study at the discretion of the treating pulmonologist and rheumatologist, including digoxin, diuretics, anticoagulants (e.g. warfarin), stable immunosuppression or other anti-fibrotic therapy for at least one month prior to enrollment~Exclusion Criteria:~1. Resting PAH (mPAP \> 25mmHg) on right heart catheterization~2. Other known causes of PAH including prior venous thromboembolism, HIV infection, chronic liver disease with portal hypertension, left ventricular systolic dysfunction (e.g. LVEF \< 40%), and congenital causes of PAH~3. Severe hepatic disease precluding the use of ambrisentan (AST/ALT ≥3x ULN).~4. Women who are pregnant or breastfeeding.~5. Concurrent therapy with a prostanoid or prostanoid analogue, PDE5 inhibitors, or enrolled in another active clinical study.~6. Use of any prostacyclin or endothelial receptor antagonist (ERA) within 30 days before study entry.~7. Bed or wheel chair bound or a baseline 6-Minute Walk distance (6MWD) less than 150 meters.~8. Childbearing capable women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.~9. New York Heart Association (NYHA) Classification: Class IV~10. Renal dysfunction (serum creatinine \>2.5mg/dL).~11. Uncontrolled sleep apnea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ambrisentan (Type: EXPERIMENTAL): ambrisentan dosed at either 5mg or 10mg orally once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).